Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer

Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer

PurposeTriple-negative breast cancer (TNBC) is a subtype associated with poor prognosis and for which there are limited therapeutic options. The purpose of this study was to evaluate the efficacy of ENMD-2076 in p53-mutated TNBC patient-derived xenograft (PDX) models and describe patterns of termina...

Full description

Bibliographic Details
Main Authors: Anastasia A. Ionkina, John J. Tentler, Jihye Kim, Anna Capasso, Todd M. Pitts, Karen A. Ryall, Rebekah R. Howison, Peter Kabos, Carol A. Sartorius, Aik Choon Tan, S. Gail Eckhardt, Jennifer R. Diamond
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-05-01
Series:Frontiers in Oncology
Subjects:
triple negative breast cancer
ENMD-2076
targeted therapy
aurora kinase A
senescence
resistance mechanisms
Online Access:http://journal.frontiersin.org/article/10.3389/fonc.2017.00094/full

Internet

http://journal.frontiersin.org/article/10.3389/fonc.2017.00094/full

Similar Items